UBS Group

UBS Group’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

UBS Group’s Portfolio PRVL Stock Details PRVL Fund Activity

Upgrade to unlock

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell
2020 Q4	$56K	Sell
2020 Q3	$694K	Sell
2020 Q2	$1.09M	Sell
2020 Q1	$908K	Sell
2019 Q4	$1.22M	Buy
2019 Q3	–	Sell
2019 Q2	$138K	Buy